Expand / Collapse search
Watch TV
Menu

This material may not be published, broadcast, rewritten, or redistributed. ©2022 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.

NERVOUS SYSTEM HEALTH
Published

Pfizer's Lyrica shows no relief from post-traumatic nerve pain

By | Reuters
A company logo is seen at a Pfizer office in Dublin, Ireland November 24, 2015. Pfizer Inc said on November 23 it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. REUTERS/Cathal McNaughton

A company logo is seen at a Pfizer office in Dublin, Ireland November 24, 2015. Pfizer Inc said on November 23 it would buy Botox maker Allergan Plc in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. REUTERS/Cathal McNaughton (Copyright Reuters 2015)

NEWYou can now listen to Fox News articles!

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study.

The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday.

Currently, there is no approved treatment in the United States for post-traumatic neuropathic pain.

Lyrica, which generated $1.22 billion in sales in the third quarter, is already approved to treat nerve pain associated with diabetes, shingles, spinal cord injury and fibromyalgia.

More on this...